Roche will acquire Sweden’s Saga Diagnostics for $595 million, integrating its Pathlight molecular residual disease (MRD) platform into Roche’s Foundation Medicine unit. Pathlight, launched in 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results